A new treatment for proteinuria, specifically for adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, is Fabhalta (iptacopan). This medication is the first and only complement inhibitor approved by the FDA for reducing proteinuria in this specific patient population.
Understanding Proteinuria and IgAN
Proteinuria is the presence of high levels of protein in the urine. While it can stem from relatively minor issues like dehydration or intense exercise, persistent proteinuria often indicates underlying kidney problems requiring treatment. Primary immunoglobulin A nephropathy (IgAN) is a chronic kidney disease where IgA antibodies build up in the kidneys, leading to inflammation and damage. This can result in significant proteinuria and potential kidney failure.
Fabhalta: A Novel Approach
Fabhalta works by inhibiting the complement system, a part of the immune system that contributes to the inflammation in IgAN. By targeting this specific pathway, Fabhalta aims to reduce the amount of protein leaking into the urine, slowing disease progression.
Other treatments for proteinuria exist and are chosen based on the underlying cause. These include:
- Statin therapy: Some studies suggest statins can be renoprotective and lower proteinuria levels.
- Enteric budesonide: Targeted to the ileocecal region, this medication has shown promise in ameliorating proteinuria in IgA nephropathy.
- Hydroxychloroquine: This antimalarial drug with immunomodulatory effects may be beneficial in some cases of IgA nephropathy.
- Inaxaplin: Studies have shown promise in reducing proteinuria in specific populations but more research is needed.
It's crucial to remember that treatment for proteinuria depends heavily on the underlying cause. A healthcare professional needs to diagnose the condition and determine the best course of action. The information provided here should not be considered medical advice.
